常规MRI与CT特征在识别WHO II级胶质瘤IDH1突变及1p/19q共缺失中的诊断价值
该回顾性研究纳入189例WHO II级胶质瘤患者,分析术前常规MRI与CT特征对IDH突变和1p/19q共缺失状态的预测能力。IDH突变组钙化频率更高且T1增强频率更低;1p/19q共缺失组钙化频率更高,而T2WI均匀信号、病灶边缘锐利、T2/FLAIR失配征及室管膜下区受累频率更低。联合参数诊断1p/19q共缺失的AUC达0.848。
要点
- IDH突变型WHO II级胶质瘤更常见钙化(25.2% vs 2.4%)且T1增强更少(20.4% vs 38.1%)。
- 1p/19q共缺失型更常见钙化(46.67% vs 2.6%),而T2WI均匀信号、边缘锐利等征象更少见。
- 联合影像特征诊断1p/19q共缺失的AUC为0.848,提示常规CT/MRI可作为无创预测方法。
关键影像表现/征象
- IDH突变组钙化频率高于IDH野生组(25.2% vs 2.4%,p=0.006),T1增强频率低于IDH野生组(20.4% vs 38.1%,p=0.028)。
- 1p/19q共缺失组钙化频率高于非共缺失组(46.67% vs 2.6%,p<0.001)。
- 1p/19q共缺失组T2WI均匀信号频率低于非共缺失组(12.0% vs 31.6%,p=0.014)。
- 1p/19q共缺失组病灶边缘锐利频率低于非共缺失组(14.7% vs 43.0%,p=0.010)。
- 1p/19q共缺失组T2/FLAIR失配征频率低于非共缺失组(22.7% vs 50.9%,p=0.001),室管膜下区受累频率低于非共缺失组(64.0% vs 15.8%,p=0.021)。
诊断标准与关键数值
- IDH突变预测:钙化频率25.2% vs 2.4%(p=0.006),T1增强频率20.4% vs 38.1%(p=0.028)。
- 1p/19q共缺失预测:钙化频率46.67% vs 2.6%(p<0.001),T2WI均匀信号12.0% vs 31.6%(p=0.014),边缘锐利14.7% vs 43.0%(p=0.010),T2/FLAIR失配征22.7% vs 50.9%(p=0.001),室管膜下区受累64.0% vs 15.8%(p=0.021)。
- 联合参数诊断1p/19q共缺失的AUC为0.848。
临床应用与阅片要点
- 对于WHO II级胶质瘤,出现钙化且T1无增强提示IDH突变可能。
- 无钙化、T2WI均匀信号、边缘锐利、室管膜下区受累及T2/FLAIR失配征提示1p/19q非共缺失可能。
- 联合常规MRI与CT特征有助于无创预测分子分型,但需结合病理及分子检测确认。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: The classification of patients based on pathology and molecular features is important for improving WHO grade II glioma patient prognosis, especially for the initially diagnosed patients. Less invasive and more convenient methods for the prediction of the pathological type and gene status are desired.
MATERIALS AND METHODS: This study investigates the ability to use conventional magnetic resonance imaging (MRI) and computed tomography (CT) features for determining the Isocitrate Dehydrogenase (IDH)-mutant and 1p/19q-codeletion status, through a retrospective review of information obtained from 189 WHO grade II glioma patients. Diffuse astrocytoma (IDH-mutant), Diffuse astrocytoma (IDH- wildtype) and Oligodendroglioma (IDH-mutant and 1p/19q co-deletion) were included in this cohort. All patients were divided into IDH-mutant group and IDH-wildtype group according to the IDH R132H mutation status. Moreover, all patients were divided into 1p/19q co-deletion group and 1p/19q non-codeletion group according to the 1p and 19q chromosome status. Patients underwent pre-operative CT and MRI scans, followed by operation and histopathological analyses, including immunohistochemistry and polymerase chain reaction analysis for IDH mutants, and fluorescence capillary electrophoresis analysis for the 1p/19q co-deletion. The χ2 test, logistical regression and receiver operating characteristic curve analysis were conducted for statistical analysis.
RESULTS: IDH-mutant group patients exhibited a higher calcification frequency (25.2% vs 2.4%, p = 0.006) and lower frequency of T1 enhancement (20.4% vs 38.1%, p = 0.028) comparing patients in IDH-wildtype group, while 1p/19q co-deletion group patients exhibited a higher calcification frequency (46.67% vs 2.6%, p < 0.001) and lower homogenous signal frequency in T2WI (12.0% vs 31.6%, p = 0.014), sharp lesion margins (14.7% vs 43.0%, p = 0.010), T2/fluid attenuated inversion recovery mismatch signs (22.7% vs 50.9%, p = 0.001), and subventricular zone involvement (64.0% vs 15.8%, p = 0.021) comparing patients in 1p/19q non-codeletion group. According to the results of receiver operating characteristic analysis, these features were observed to have certain diagnostic abilities, especially with regard to combination parameters, which had a high diagnostic capability, with an area under the curve of 0.848.
CONCLUSION: Conventional MRI and CT features, which still represent the most convenient and widely used predictive method, might be a promising noninvasive predictor for differentiating between varied WHO grade II gliomas. Patients with calcification and T1 nonenhancement are more likely to be IDH-mutant. Moreover, patients with noncalcification, homogenous signal, sharp lesion margins, subventricular zone involvement on T2 and T2/fluid attenuated inversion recovery mismatch signs are more likely to be 1p/19q non-codeletion.
引用
- Zhao K, Sun G, Wang Q, et al. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas. Acad Radiol. 2020. PMID: 32359929. doi:10.1016/j.acra.2020.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。